Gilead's $42.5K Priced HIV Drug Could Be Made At Just $40 Annually, Campaigners Urge Company To Slash Price
Portfolio Pulse from Vandana Singh
Campaigners are urging Gilead Sciences Inc. to significantly reduce the price of its HIV prevention drug, lenacapavir, which is currently priced at $42,250 annually but could be produced for just $40. The drug, sold as Sunlenca, has shown 100% efficacy in preventing HIV in cisgender women in a Phase 3 trial. Gilead is awaiting further clinical trial data and regulatory approvals before pricing lenacapavir for prevention.
July 24, 2024 | 7:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Gilead Sciences is under pressure to reduce the price of its HIV prevention drug, lenacapavir, which is currently priced at $42,250 annually but could be produced for just $40. The drug has shown 100% efficacy in a Phase 3 trial.
The news highlights the potential for significant cost reduction in Gilead's HIV drug, which could lead to increased accessibility and market penetration. The positive Phase 3 trial results further strengthen the drug's market potential, likely boosting investor confidence.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100